Chronic migraine is not a single disease. It is a clinical phenotype produced by at least four mechanistically distinct upstream drivers: mitochondrial bioenergetic failure that lowers the threshold for cortical spreading depression, dural mast cell activation that sensitizes the trigeminovascular system, gut-brain axis dysfunction that produces sustained low-grade neuroinflammation, and hormonal-vasomotor instability that triggers the vascular component. Most patients have features of more than one driver. Each driver responds to different interventions. When standard migraine treatment (triptans for acute, CGRP antibodies for prevention, beta blockers and topiramate for older prevention) produces incomplete response, it is usually because the dominant driver in the specific case is not the one those medications target. The fix is not a stronger CGRP antibody. The fix is identifying which mechanism is operating and addressing it at its upstream point.
The clinical pattern that defines treatment-resistant migraine
A patient presents with migraine that has progressively transformed from episodic (fewer than 15 headache days per month) to chronic (15 or more headache days per month, with 8 or more meeting full migraine criteria). The migraines often started in adolescence or early adulthood. They were initially manageable with over-the-counter analgesics and lifestyle modification. Over the following decade, the frequency increased. The duration increased. The intensity worsened. The associated symptoms expanded: visual aura, vestibular features, autonomic instability, gastrointestinal symptoms, severe photophobia and phonophobia, brain fog that persists between attacks.
The treatment cascade follows the standard neurological algorithm. Triptans for acute attacks. NSAIDs and combination analgesics. Beta blockers (propranolol, metoprolol) for prevention. Topiramate for prevention. Amitriptyline or other tricyclics. Botulinum toxin injections for chronic migraine. The newer CGRP-targeting antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab). Atogepant, rimegepant, ubrogepant for newer oral options.
Many patients respond to one or more of these. Some respond substantially. A significant fraction respond partially or not at all. The CGRP antibody class, which represented a major advance, demonstrates approximately 50 to 60 percent response rates in clinical trials, with response defined as a 50 percent reduction in monthly migraine days. This means 40 to 50 percent of patients do not achieve even a 50 percent reduction. For chronic migraine patients with 25 headache days per month, even a successful response of 50 percent reduction still leaves 12 headache days per month. The treatment is meaningful but incomplete for many.
The alternative interpretation, supported by primary research that has not yet translated into clinical practice, is that migraine is a downstream readout of several distinct upstream lesions. The medications target specific pathways in the migraine cascade. They do not address the lesions that are continuously generating the input into the cascade.
Why the standard migraine model produces variable results
The dominant current model of migraine pathophysiology centers on neurovascular activation involving the trigeminovascular system. Cortical spreading depression (CSD) is a wave of depolarization across the cortex. The CSD activates trigeminal afferents. Trigeminal activation releases neuropeptides including CGRP, substance P, and PACAP. These produce vasodilation, plasma protein extravasation, mast cell degranulation in the dura, and sensitization of pain pathways.
What the model does not adequately describe is the upstream question: what determines whether a given patient develops cortical spreading depression in the first place? What lowers the threshold over time, transforming episodic migraine into chronic migraine? What determines which patients respond well to CGRP blockade and which do not?
The four mechanistic drivers of chronic migraine
Driver 1: Mitochondrial bioenergetic failure
The migraine brain is bioenergetically compromised. Magnetic resonance spectroscopy studies have documented reduced phosphocreatine levels, slowed phosphocreatine recovery after exercise, and elevated lactate-to-creatine ratios in the brains of migraine patients compared to controls.
CSD is energetically expensive. It involves massive ion-pumping demand to restore neuronal membrane potential after the depolarization wave. A brain with adequate ATP capacity can recover without producing sustained dysfunction. A brain with compromised ATP capacity cannot. The CSD threshold falls.
This mechanism is supported by evidence for mitochondrial-targeted prophylactic supplements. High-dose riboflavin (400 mg daily) reduces migraine frequency in multiple randomized controlled trials. CoQ10 supplementation reduces migraine frequency. Magnesium is essential for ATP synthase function and is the most well-established prophylactic supplement in migraine.
The framework predicts that patients with dominant Driver 1 will respond particularly well to mitochondrial support: riboflavin, CoQ10 (ubiquinol form), magnesium glycinate. They will also respond well to addressing the upstream causes of their mitochondrial compromise, which include the CD38-NAD+-SIRT3 cascade and iron-sulfur cluster damage.
The clinical signature of Driver 1 migraine includes worsening with sleep deprivation, with skipped meals, with intense exercise. Patients often describe their migraines as "energy crashes" with neurological features. Brain fog persists between attacks.
Driver 2: Dural mast cell activation
The dura mater is densely infiltrated with mast cells. They release histamine, tryptase, chymase, prostaglandin D2, leukotrienes, and TNF-alpha during activation. Each of these mediators contributes to the migraine cascade.
Patients with MCAS have a substantially elevated prevalence of migraine. Patients with chronic migraine have a substantially elevated prevalence of MCAS-spectrum symptoms. The four-pattern MCAS framework described in the article on treatment-resistant MCAS applies.
Mast cell stabilizers including cromolyn, ketotifen, and quercetin produce meaningful migraine reduction in patients with dominant Driver 2. H1 antihistamines (cetirizine, fexofenadine) and H2 antihistamines (famotidine) reduce migraine frequency in some patients.
The clinical signature of Driver 2 migraine includes triggers consistent with mast cell activation: heat, alcohol (particularly red wine), aged cheeses, fermented foods, weather changes, perimenstrual cycles, and stress. Concurrent symptoms include flushing, rapid heart rate, skin reactions, and food sensitivities.
Driver 3: Gut-brain axis dysfunction and neuroinflammation
The gut-brain axis is bidirectional. Lipopolysaccharide (LPS) translocation across a compromised gut barrier activates TLR4 receptors on innate immune cells throughout the body, including microglia in the brain. Microglial activation produces neuroinflammation that lowers the cortical spreading depression threshold.
The depletion of obligate anaerobic core taxa and expansion of facultative anaerobes produces the dysbiotic state described in the recurrent SIBO article. SIBO specifically has been documented at elevated prevalence in migraine populations.
Vagal afferent dysfunction is increasingly recognized. Vagal nerve stimulation has been FDA-approved for migraine. Patients with low vagal tone (often the same patients with POTS or dysautonomia) have higher migraine frequency.
The clinical signature of Driver 3 migraine includes concurrent gastrointestinal symptoms, food sensitivities, post-meal worsening, and onset or worsening of migraine following antibiotic courses or infections.
Driver 4: Hormonal-vasomotor instability
Estrogen withdrawal triggers menstrual migraine. Pregnancy often improves migraine in the second and third trimesters. Perimenopause produces some of the most dramatic worsening of migraine in many patients' lifetime patterns.
Estrogen modulates serotonin synthesis and receptor sensitivity, magnesium uptake, CGRP synthesis, nitric oxide synthase activity, and mast cell stability. Driver 4 connects migraine to the broader perimenopausal cascade described in the perimenopause article.
The clinical signature of Driver 4 includes menstrual association, perimenopausal worsening, postpartum onset, and concurrent perimenopausal symptoms.
When drivers combine
Most chronic migraine cases have features of more than one driver. Driver 1 (mitochondrial) and Driver 2 (mast cell) frequently combine because the inflammatory tone that drives mast cell activation also produces mitochondrial dysfunction through the CD38 pathway. Driver 2 and Driver 3 frequently combine because Pattern A barrier-driven MCAS is mechanistically the same lesion as the gut-brain axis dysfunction. Driver 4 often emerges as dominant in patients who had Drivers 1, 2, or 3 operating sub-clinically until perimenopause unmasked them.
Why CGRP antibodies work for some and not others
The CGRP antibody class blocks calcitonin gene-related peptide or its receptor. For patients whose migraine biology is dominantly driven through CGRP-dependent pathways, the response is excellent. For patients whose migraine has substantial contributions from non-CGRP pathways, the response is partial or absent.
The CGRP antibody non-response, in this framework, is not necessarily failure of the medication. It is the readout of a case where the medication is operating downstream of a lesion that the medication does not address. Adding upstream work to CGRP antibody treatment often improves response substantially in cases where the antibody alone was insufficient.
What restoration looks like
For Driver 1 (mitochondrial) cases: high-dose riboflavin (400 mg daily), CoQ10 ubiquinol (200-400 mg daily), magnesium glycinate (400-600 mg daily). Address upstream causes of bioenergetic compromise. Sleep optimization and consistent meal timing.
For Driver 2 (mast cell) cases: mast cell stabilization (cromolyn, ketotifen, or quercetin), low-histamine dietary trial, H1 and H2 antihistamine combination where appropriate, and addressing the upstream driver of mast cell activation.
For Driver 3 (gut-brain) cases: address SIBO if present, comprehensive gut workup, vagal tone restoration (slow-paced breath work, cold exposure within tolerance, vagal nerve stimulation devices when accessible).
For Driver 4 (hormonal) cases: assess hormonal status comprehensively including progesterone, consider hormone replacement therapy under appropriate medical supervision, address the estrobolome (see the endometriosis article).
The full sequence operates on the timescale of six to twelve months for substantial improvement.
This is the approach a Biomelogic consultation works through
The deliverable is a written mechanistic analysis that places the migraine case in HCM terms, identifies the dominant driver, names the contributing drivers, and recommends sequencing for the patient's existing clinical team. Biomelogic does not prescribe and does not replace the neurologist managing the case. Migraine requires ongoing specialist medical care.
Frequently asked questions about chronic and treatment-resistant migraine
Why don't CGRP antibodies work for me? The most common reason is that the dominant driver in the case is not predominantly CGRP-mediated. CGRP antibodies act downstream of all four drivers and work best when the case is dominantly mediated through the CGRP-dependent component.
Can I come off my preventive medications? That decision is between you and your neurologist. The framework is not a strategy for stopping prescription medication.
What about vestibular migraine? Vestibular migraine sits in the same framework. Driver 1 (mitochondrial) is often particularly dominant because the vestibular system is bioenergetically expensive. Driver 3 (gut-brain) is also frequently dominant.
Why does my migraine get worse in perimenopause? This is Driver 4 becoming dominant. The hormonal stability that buffered the underlying drivers in younger years is lost.
Should I try riboflavin and CoQ10? The evidence base is reasonable. Riboflavin at 400 mg daily, CoQ10 ubiquinol at 200-400 mg daily, and magnesium glycinate at 400-600 mg daily are reasonable additions to most preventive regimens.
Is Mohammed Attallah a doctor? No. Mohammed Attallah is an independent systems-biology researcher and developer of the Host Capacity Model. He is not a licensed clinician.
What does a Biomelogic migraine consultation cost? The Standard Consultation is $650 one time, which includes the case review, the live session, and the written mechanistic analysis.
How do I get started? The lowest-friction starting point is the free 15-minute discovery call.
Working with Biomelogic on chronic migraine
If the patterns described above resonate with the migraine case you have been navigating, a Biomelogic consultation may be useful. The lowest-friction starting point is the free 15-minute discovery call. For patients ready to proceed directly to a full case workup, the Gate 1 intake form is the starting point.